No Data
Gyre Therapeutics Shareholders Approve Directors and Governance Measures
Top Gyre Therapeutics Insider Quietly Cashes Out in a Major Stock Move
Top Executive's Bold Move at Gyre Therapeutics Stirs Investor Buzz
Top Executive Makes Notable Move With Gyre Therapeutics Stock
Gyre Therapeutics' F351 NDA Accepted for Priority Review
Express News | Gyre Therapeutics: Plans to File Ind Application in U.S. by 2026 End; if Ind Becomes Effective, to Initiate Phase 2 Clinical Trial